Quarterly ResultMay 13, 2026, 04:02 PM
MDxHealth Exits Resolve UTI Business; Q1 Revenue $27.4M
AI Summary
MDxHealth reported its Q1 2026 financial results, with revenue increasing 13% to $27.4 million and net loss decreasing 4% to $(8.9) million. The company announced a strategic decision to discontinue its Resolve UTI offering and Plano, Texas laboratory operations due to an uncertain reimbursement landscape, aiming to refocus on its core prostate cancer precision diagnostics business. MDxHealth also updated its 2026 revenue guidance for the core cancer business to $110-115 million, representing 20-26% year-over-year growth, and disclosed a contested $10.4 million Medicare recoupment decision related to Resolve mdx claims.
Key Highlights
- MDxHealth will discontinue its Resolve UTI offering and Plano, Texas lab operations.
- Q1 2026 revenue increased 13% year-over-year to $27.4 million.
- Pro-forma adjusted core revenue (excluding Resolve business) rose 11% to $23.9 million.
- Net loss for Q1 2026 decreased 4% to $(8.9) million.
- Adjusted EBITDA was $(4.3) million, a 226% increase in loss compared to prior year.
- Updated 2026 revenue guidance for core cancer business (ex-Resolve) is $110-115 million, representing 20-26% YoY growth.
- Cash and cash equivalents stood at $43.2 million as of March 31, 2026.
- Company received a $10.4 million Medicare recoupment decision for Resolve mdx claims, which it is contesting.